Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370875 · ClinicalTrials.gov registry record · NA
rTMS and Botulinum Toxin in Benign Essential Blepharospasm
A NA study of Benign Essential Blepharospasm, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02370875 is a NA study of Benign Essential Blepharospasm that has completed, run by University of Florida. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02370875, a NA study of Benign Essential Blepharospasm, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therapy can be easily combined with BoNT injections to enhance the effects of BoNT in BEB.
Conditions Studied
Interventions
- DEVICE Magstim RapidStim2
- DEVICE Sham Magstim RapidStim2
Study Locations (1)
Florida
- Center for Movement Disorders and Neurorestoration - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370875
The ClinicalTrials.gov registry entry for NCT02370875 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Essential Blepharospasm appearing as the primary indexed condition, and to 2 interventions - of which Magstim RapidStim2 is the first listed.
NCT02370875 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02370875 about?
NCT02370875 is a clinical study titled "rTMS and Botulinum Toxin in Benign Essential Blepharospasm". Benign essential blepharospasm (BEB) is a functionally disabling focal dystonia. Botulinum neurotoxin (BoNT) therapy is suboptimal in many BEB patients. Repetitious transcranial magnetic stimulation (rTMS) therapy is a promising noninvasive therapy and has shown positive benefits in BEB. rTMS therap...
What is the current status of trial NCT02370875?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2015-02. Estimated completion is 2017-11.
What conditions does trial NCT02370875 study?
This clinical trial studies the following conditions: Benign Essential Blepharospasm.
What interventions are being tested in trial NCT02370875?
The interventions under investigation include: Magstim RapidStim2 (DEVICE), Sham Magstim RapidStim2 (DEVICE).
Who is sponsoring clinical trial NCT02370875?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02370875 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Essential Blepharospasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.